Shares of common stock in connection with securities purchase agreements Shares of Common Stock to be Purchased by Common Stock Warrants Shares of Common Stock to be Purchased by Common Stock Warrants Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total future lease payments Lessee, Operating Lease, Liability, to be Paid Number of cases pending Loss Contingency, Pending Claims, Number Additions charged to expense Accounts Receivable, Credit Loss Expense (Reversal) Restricted stock units unvested Unvested Restricted Stock Units [Member] Unvested share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Interest and other income, net Interest And Other Income, Net Interest And Other Income, Net Entity Address, Postal Zip Code Entity Address, Postal Zip Code Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Exercise of warrants (in shares) Class of Warrant or Right, Warrants Exercised The number of class of warrant or right exercised. 2024 Long-Term Debt, Maturity, Year Two Accrued balances - Accounts payable and accrued expense Accrued distribution expenses Accounts Receivable Allowances and Accruals - Accounts Payable and Accrued Expenses For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible, classified within Accounts payable and other accrued expenses. Royalty receivable Cumulative Royalty Receivable Cumulative sum of the carrying amounts of royalty receivable as of the balance sheet date. Debt Instrument [Axis] Debt Instrument [Axis] Number of guaranteed royalty payments Number Of Guaranteed Royalty Payments Number Of Guaranteed Royalty Payments Property and equipment, gross Property, Plant and Equipment, Gross Changes in Allowance for Bad Debt Financing Receivable, Current, Allowance for Credit Loss [Table Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Royalty Obligation Activity Royalty Obligation Activity [Table Text Block] Royalty Obligation Activity Additional paid-in capital Additional Paid in Capital At-the-market offering At The Market Offering [Member] At The Market Offering Computer, network equipment and software Computer, Network Equipment and Software [Member] Assets which are related to computer, network equipment and software. Statistical Measurement [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Estimated discount rate Lessee, Operating Lease, Discount Rate Depreciation and amortization Depreciation Proceeds from refinancing of debt Proceeds from Issuance of Debt Vested restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Interest rate Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Elective redemption percentage of debt Elective redemption percentage of debt Elective redemption percentage of debt. Repayment of debt Repayments of Debt Stand-alone product Stand Alone Product [Member] Stand Alone Product Other, net Other Noncash Income (Expense) Trade receivables Accounts Receivable, before Allowance for Credit Loss Senior secured notes due 2025 - first additional offering First Additional Offering [Member] The first additional offering of the loan agreement. Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potentially antidilutive derivatives excluded from losses per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Debt Maturity Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Eighth Month Eighth Month [Member] Eighth Month Contract assets Contract and other receivables Other Receivables, Gross, Current Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Repurchase price percentage Debt Instrument, Redemption Price, Percentage Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Right-of-Use Assets and Lease Obligations Lessee, Operating Leases [Text Block] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Payments for loan acquisition costs Payments of Financing Costs Liability related to the sale of future revenue, net at December 31, 2021 Liability related to the sale of future revenue, net (includes current portion of $1,445) Liabilities, Sale of Future Royalties Liabilities, Sale of Future Royalties Premium on early retirement of debt Premiums Paid, Early Retirement of Debt Premiums Paid, Early Retirement of Debt Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Restricted Stock Units Awards Nonvested Restricted Stock Shares Activity [Table Text Block] Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Number of annual royalty payments receivable Number of Annual Royalty Payments Receivable Number of annual royalty payments receivable by the entity for the use of its rights and property by another party. Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Private equity Private equity [Member] Private equity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Warrants issued to purchase common stock (in shares) Class Of Warrant Or Right Warrants Issued During Period The number of warrants issued during the period. Net proceeds Net Proceeds After Placement Agent Fees, Expenses, and Offering Expenses Payable Net Proceeds After Placement Agent Fees, Expenses, and Offering Expenses Payable Employee Stock Employee Stock [Member] Trade and other receivables, net Increase (Decrease) in Accounts and Other Receivables Award Type [Axis] Award Type [Axis] Automatic renewal period of agreement Automatic Renewal Period of Agreement Period for which the agreement is renewed automatically. Net cash used for operating activities Net Cash Provided by (Used in) Operating Activities Lease liabilities, current Operating Lease, Liability, Current Vested and expected to vest as of June 30, 2022 (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date Fair Value The estimated fair value of nonvested equity-based awards on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan) as of grant date. Warrants [Abstract] Warrants Liability [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Change in fair value of warrant Adjustments to Additional Paid in Capital, Fair Value of Warrants Issued Amount of increase in additional paid in capital (APIC) resulting from the issuance of fair value of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Balance at December 31, 2021 Balance at June 30, 2022 Accounts Receivable Allowances and Accruals For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible and accruals. Total liabilities Liabilities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Revenues and Trade Receivables, Net Revenues and Trade Receivables, Net [Text Block] The entire disclosure of revenues and trade receivables, net. Common stock issued, value Stock Issued During Period, Value, New Issues Purchased technology-based intangible Technology-Based Intangible Assets [Member] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Revenue Recognition and Performance Obligations Revenue from Contract with Customer [Policy Text Block] Indivior Commercial exploitation agreement with Indivior Commercial Exploitation Agreement with Indivior [Member] The commercial exploitation agreement with Indivior. Document Type Document Type Useful Lives Property, Plant and Equipment, Useful Life Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Severance costs Severance Costs Unvested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value 12.5% Senior Secured Notes and Loans Payable Debt Disclosure [Text Block] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract] Supplemental agreement with Indivior additional process patent rights to the company Supplemental Agreement with Indivior Additional Process Patent Rights to the Company [Member] The supplemental commercial exploitation agreement with Indivior earnings through the issuance of additional process patent rights to the company. Proceeds from common stock issued under private equity offering, net Proceeds from Issuance Private Offering Proceeds from Issuance Private Offering Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accounts Receivable Allowances and Accruals [Roll Forward] Accounts Receivable Allowances and Accruals [Roll Forward] Accounts Receivable Allowances and Accruals Deferred revenue Increase (Decrease) in Deferred Revenue Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Loans payable, current Loans Payable, Current 2025 Long-Term Debt, Maturity, Year Three Subsequent event Subsequent Event [Member] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Revenue Revenue Benchmark [Member] Document Period End Date Document Period End Date Put option Put Option [Member] First 7 Months First Seven Months [Member] First Seven Months Proprietary product sales, net Proprietary Product Sales [Member] The aggregate revenue generated from proprietary product sales. Pro rata portion of target bonus Pro Rata Portion of Target Bonus Pro Rata Portion of Target Bonus Total assets Assets Write-downs charged against the allowance Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Litigation settlement, amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] License and royalty revenue License and Royalty Revenue [Member] The aggregate revenue generated from licensing and royalties. Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accrued expenses Total accrued expenses Accrued Liabilities, Current Liability related to the sale of future revenue, net Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Fair value of put option Long-Term Debt, Fair Value Accounting Policies [Abstract] Accounting Policies [Abstract] Neurelis IPR Litigation Neurelis IPR Litigation [Member] Neurelis IPR Litigation Manufacture and supply revenue Manufacture and Supply Revenue [Member] The aggregate revenue generated from manufacture and supply. Agreement term Agreement Term Agreement Term Accrued compensation Employee-related Liabilities, Current Variable lease expense Variable Lease, Cost Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Months within the effective date of the amendment Time Frame within the Effective Date of the Amendment Time Frame within the Effective Date of the Amendment Amortization of debt issuance costs and discounts Amortization expense, deferred debt issuance costs and debt discounts Amortization of Debt Issuance Costs and Discounts Net Loss Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Valuation Assumptions for Determination of Fair Value of Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Award Type [Domain] Award Type [Domain] Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Unrecognized compensation cost, recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Interest and other income, net Gain (Loss) on Extinguishment of Debt Percentage of cash proceeds Repurchase Offer, Percentage of Cash Proceeds Received Repurchase Offer, Percentage of Cash Proceeds Received Components of Identifiable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Finished goods Inventory, Finished Goods, Gross Summary of Other Non-current Assets Schedule of Other Assets, Noncurrent [Table Text Block] Entity Registrant Name Entity Registrant Name Common stock issued (in shares) Stock Issued During Period, Shares, New Issues Research and development, project duration Research and Development, Project Duration Research and Development, Project Duration Subsequent Events Subsequent Events [Text Block] Consulting fee Consulting Fee Consulting Fee Interest expense related to the sale of future revenue, net Interest Expense, Sale of Future Revenues Interest Expense, Sale of Future Revenues Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Minimum annual royalty receivable Minimum Annual Royalty Receivable Minimum annual royalty receivable by the entity for the use of its rights and property by another party. Purchased patent Patents [Member] Entity Address, City or Town Entity Address, City or Town Interest expense related to the sale of future revenue, net Interest expense related to the sale of future revenue Interest Expense, Sale of Future Revenues (Excluding Amortization) Interest Expense, Sale of Future Revenues (Excluding Amortization) Leases [Abstract] Leases [Abstract] Revenues and Trade Receivables, Net [Abstract] Revenues and Trade Receivables, Net [Abstract] Costs and expenses: Operating Expenses [Abstract] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Royalty Royalty [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Accounting Standards Update [Axis] Accounting Standards Update [Axis] Financial Instruments – Fair Value Measurements Fair Value Disclosures [Text Block] Share price (in dollars per share) Share Price Other non-current Assets Other Assets Disclosure [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Warrants Warrants Disclosure [Text Block] The entire disclosure for warrants. Senior secured notes due 2025 - second additional offering Second Additional Offering [Member] The second additional offering of the loan agreement. Deferred revenue Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Supplemental agreement with Indivior Supplemental Agreement with Indivior [Member] The supplemental commercial exploitation agreement with Indivior. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Vested or expected to vest at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Sale of Future Revenue [Roll Forward] Sale of Future Revenue [Roll Forward] Sale of Future Revenue Raw material Inventory, Raw Materials, Gross Accounts payable Increase (Decrease) in Accounts Payable Company Overview and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Subsequent Events [Abstract] Subsequent Events [Abstract] Concentrations of risk Concentration Risk, Percentage Right to sell common stock, value Right to Sell Common Stock, Value Right to Sell Common Stock, Value License agreement term License Agreement Term License agreement term period. Income Taxes Income Tax Disclosure [Text Block] Premium paid to retire debt Payment for Debt Extinguishment or Debt Prepayment Cost Sales Related Allowances and Accruals Sales Related Allowances and Accruals [Table Text Block] Tabular disclosure of valuation of sales allowance and accruals for receivables due a company that are expected to be uncollectible including a rollforward of the balance. Notice period of intent not to renew agreement Notice Period for Not to Renew Agreement Notice period of intent not to renew agreement, prior to the expiration of the initial or renewal term. Credit Facility [Domain] Credit Facility [Domain] Amortization expense Amortization of Intangible Assets Number of products approved by food and drug administration Number Of Products Approved By Food And Drug Administration Number Of Products Approved By Food And Drug Administration Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Cash payments for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Net loss per share - basic (in dollars per share) Loss per common share – basic (in dollars per share) Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Number of quarterly payments Debt Instrument, Principal, Number Of Quarterly Payments Debt Instrument, Principal, Number Of Quarterly Payments Payments / credits Accounts Receivable Allowances, Credits and payments For an unclassified balance sheet, a valuation of sales allowance for receivables related to credits due a company that are expected to be uncollectible. Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total stockholders’ deficit Balance Balance Stockholders' Equity Attributable to Parent Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value MAM Pangolin Royalty , LLC Marathon Pangolin Royalty LLC [Member] Marathon Pangolin Royalty LLC Entity Interactive Data Current Entity Interactive Data Current Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Less: accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Other Other Assets, Miscellaneous, Noncurrent Exercised, forfeited, expired (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Forfeitures And Expirations In Period WeightedAverageExercisePrice Weighted average price of options that were either exercised, forfeited or expired. Accumulated Deficit Retained Earnings [Member] Unrecognized compensation expense related to non-vested stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Common Stock Common Stock [Member] License agreement with Sunovion Pharmaceuticals, Inc. upfront License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member] The license agreement made with sunovion pharmaceuticals, inc. advance payments. Public equity Public equity [Member] Public equity Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective annual interest rate Debt Instrument, Interest Rate, Effective Percentage Issuance [Axis] Issuance [Axis] Issuance Document Quarterly Report Document Quarterly Report Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Senior secured notes due 2025 Twelve Point Five, Senior Secured Notes due June 30, 2025 [Member] A debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer. Lease liabilities Operating Lease, Liability, Noncurrent Cardinal Cardinal [Member] Cardinal Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Axis] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Number of leases Number of Operating Leases Number of operating leases. Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Shares purchased Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Lincoln park agreement Lincoln Park Agreement [Member] Lincoln Park Agreement Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Litigation Case [Domain] Litigation Case [Domain] Vested restricted stock units APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Document Fiscal Year Focus Document Fiscal Year Focus Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Unvested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Intangible assets, gross Finite-Lived Intangible Assets, Gross Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Right-of-use assets, net Right of use assets Operating Lease, Right-of-Use Asset Vested or expected to vest at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Inventories, net Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Trade and other receivables, net Trade and other receivables, net Trade and other receivables, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade and other receivables). Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Manufacture and supply Manufacturing and supply [Member] Primary financial statement caption encompassing Manufacturing and supply expense. Adjustments to reconcile net loss to net cash used for operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Receivable Contract with Customer, Receivable, after Allowance for Credit Loss Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Manufacture and supply Cost of Goods and Services Sold Weighted-average number of common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Risks and Uncertainties Concentration Risk Disclosure [Text Block] Inventory, Net Schedule of Inventory, Current [Table Text Block] Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Loss Contingencies [Line Items] Loss Contingencies [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Receivables Accounts Receivable [Member] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Sale of Future Revenue Sale of Future Revenue [Text Block] Sale of Future Revenue Common stock, $0.001 par value. Authorized 250,000,000 shares; 53,343,989 and 41,228,736 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Common stock, discount on shares Common Stock, Discount on Shares Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Packaging material Inventory Packing Material Gross Amount of packaging materials expected to be sold within one year or operating cycle, if longer. Senior notes Senior Notes [Member] Cash payment representing 90 days of base pay Cash Payment Representing 90 Days of Base Pay Cash Payment Representing 90 Days of Base Pay Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Principal payments, percentage of face amount Principal Payments, Percentage of Face Amount Principal Payments, Percentage of Face Amount Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Contingencies Commitments and Contingencies Disclosure [Text Block] Fair value of warrants issued Adjustments to Additional Paid in Capital, Warrant Issued Current liabilities: Liabilities, Current [Abstract] Issuance [Domain] Issuance [Domain] Issuance Common stock, shares issued (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Haisco Pharmaceutical Group Co., Ltd, upfront payment Haisco Pharmaceutical Group Co., Ltd, Upfront Payment [Member] Haisco Pharmaceutical Group Co., Ltd, Upfront Payment Deferred revenue, current Contract with Customer, Liability, Current Accounting standards update 2016-02 Accounting Standards Update 2016-02 [Member] Income Statement Location [Domain] Income Statement Location [Domain] Duration of payment [Axis] Duration of payment [Axis] Duration of payment Amendment Flag Amendment Flag Remaining lease term Lessee, Operating Lease, Remaining Lease Term Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Operating lease expense Operating Lease, Cost Principal amount Debt Instrument, Face Amount Shares issued under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Construction in progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Provision Accounts Receivable Allowances, Provision (Reversal) Related to Sales For an unclassified balance sheet, a valuation of sales allowance for receivables related to sales due a company that are expected to be uncollectible. Other non-current assets Total other non-current assets Other Assets, Noncurrent Agreement to terminate CLA with KemPharm Agreement to Terminate CLA with KemPharm [Member] The agreement to terminate CLA with KemPharm. Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Net proceeds from issuance of initial notes, warrants and first offer rights Net Proceeds from Issuance of Initial Notes, Warrants and First Offer Rights The net cash inflow associated with the amount received from issuance of initial notes, warrants and first offer rights. Shares issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Unamortized deferred debt issuance cost and deferred debt discounts Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Other Stockholders' Equity, Other Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Material Agreements [Abstract] Material Agreements [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Options on common shares outstanding Stock options Share-Based Payment Arrangement, Option [Member] Duration of payment [Domain] Duration of payment [Domain] Duration of payment [Domain] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt Total Long-Term Debt Common stock, shares authorized (in shares) Common Stock, Shares Authorized Maximum Maximum [Member] Revenue Revenue from External Customers by Products and Services [Table Text Block] Haisco Haisco Pharmaceutical Group Co., Ltd [Member] Haisco Pharmaceutical Group Co., Ltd Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Real estate and personal property taxes Taxes Payable, Current Entity Small Business Entity Small Business License agreement with Sunovion Pharmaceuticals, Inc. License Agreement with Sunovion Pharmaceuticals, Inc. [Member] The license agreement made with sunovion pharmaceuticals, inc. Balance (in shares) Balance (in shares) Shares, Outstanding Intangible assets, net Intangible assets, net Finite-Lived Intangible Assets, Net Warrants and Rights Note Disclosure [Abstract] Warrants and Rights Note Disclosure [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Revenue [Abstract] Disaggregation of Revenue [Abstract] Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Title of 12(b) Security Title of 12(b) Security Business days Business Days after Haisco Receives Copy of Written Acknowledgement Business Days after Haisco Receives Copy of Written Acknowledgement Remaining amount available for offering Sale Of Stock, Remaining Amount Available For Offering Sale Of Stock, Remaining Amount Available For Offering Supplemental agreement with Indivior performance or event-based milestones Supplemental Agreement with Indivior Performance or Event-Based Milestones [Member] The supplemental commercial exploitation agreement with Indivior. Total costs and expenses Costs and Expenses Payables and Accruals [Abstract] Payables and Accruals [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Geographic Areas, Revenues from External Customers [Abstract] Geographic Areas, Revenues from External Customers [Abstract] Total operating lease liabilities Operating Lease, Liability Co-development and research fees Co-Development and Research Fees [Member] The aggregate revenue generated from Co-development and research fees. Liabilities and stockholders’ deficit Liabilities and Equity [Abstract] Neurelis, Inc. v. Aquestive Therapeutics, Inc. Neurelis, Inc. v. Aquestive Therapeutics, Inc. [Member] Neurelis, Inc. v. Aquestive Therapeutics, Inc. Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Contingent payments receivable in the future Contingent payments receivable in the future Potential additional payment receivable under the agreement as of the balance sheet date. These are the aggregate from any combination of (a) performance or event-based milestone payments and (b) single digit percentage royalties on net revenue earned by Indivior on sales of Suboxone and earnings through the issuance of additional process patent rights to the company. Exercised, forfeited, expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised,Forfeitures and Expirations in Period For presentations that combine terminations, the number of shares under options that were exercised, cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Remainder of 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Consideration received on sale of stock Sale of Stock, Consideration Received on Transaction Inventories, net Total inventory, net Inventory, Net Accounts payable Accounts Payable, Current Licensed product Licensed Product [Member] Licensed Product Warrants on common shares outstanding Warrant [Member] Equity distribution agreement Equity Distribution Agreement [Member] Equity Distribution Agreement Entity Filer Category Entity Filer Category Weighted-average number of common shares outstanding - basic (in shares) Weighted-average number of common shares – basic (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Days required prior to written notice Days Required Prior to Written Notice Days Required Prior to Written Notice Share-based compensation expenses Share-Based Payment Arrangement, Expense Contingencies (Note 19) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Share-based Compensation expenses [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Selling, general and administrative General and Administrative Expense [Member] Revenues Royalties related to the sale of future revenue Revenue from Contract with Customer, Excluding Assessed Tax Payments of loan costs Payments of Loan Costs Shares of common stock Shares of Common Stock Entitled to Purchasers by Pre-funded Warrants Shares of Common Stock Entitled to Purchasers by Pre-funded Warrants Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Depreciation, amortization, and impairment Depreciation, Depletion and Amortization, Nonproduction Share-Based Compensation Share-Based Payment Arrangement [Text Block] Less: allowance for doubtful accounts Allowance for doubtful accounts at beginning of the period Allowance for doubtful accounts at end of the period Accounts Receivable, Allowance for Credit Loss Share-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Severance period Severance Period Severance Period Forecast Forecast [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Payments for taxes on share-based compensation Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ deficit Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Proceeds from shares issued under employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Amortization of issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Proceeds from sale of future revenue Proceeds From Sale of Future Revenues, Net Proceeds From Sale of Future Revenues, Net Warrant exercises Warrant exercises [Member] Warrant exercises Ex-United States Non-US [Member] 12.5% Senior Secured Notes [Abstract] Senior Secured Notes [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Redemption percentage of debt under change of control provisions Redemption percentage of debt under change of control provisions Redemption percentage of debt under change of control provisions. Current Fiscal Year End Date Current Fiscal Year End Date Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Net loss per share - diluted (in dollars per share) Loss per common share – diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Payments for stock issuance costs Payments of Stock Issuance Costs Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Monetization agreement Monetization Agreement [Member] Monetization Agreement Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Securities purchase agreement Securities Purchase Agreement [Member] Securities Purchase Agreement 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Trade and Other Receivables, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Customer concentration risk Customer Concentration Risk [Member] Percent of fair value of shares, employees purchase Percent of Fair Value of Shares, Employees Purchase Percent of Fair Value of Shares, Employees Purchase Ninth through Eighteenth Month Ninth through Eighteenth Month [Member] Ninth through Eighteenth Month Entity Ex Transition Period Entity Ex Transition Period License agreement with Sunovion Pharmaceuticals, Inc milestones License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member] The license agreement made with sunovion pharmaceuticals, inc. milestones. Other income/ (expenses): Nonoperating Income (Expense) [Abstract] Days of base pay Days of Base Pay Days of Base Pay Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Less: sales-related allowances Accrued balances - Trade and other receivables, net Accounts Receivable Allowances and Accruals - Trade and Other Receivables, Net For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible, classified within trade and other receivables, net. Entity Address, Address Line One Entity Address, Address Line One Coverage duration Coverage duration Coverage duration Contract liabilities Contract with Customer, Liability Product and Service [Axis] Product and Service [Axis] Liability related to the sale of future revenue, current Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Current Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Costs of common stock issued under public equity offering Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Interest expense Interest Expense Credit Facility [Axis] Credit Facility [Axis] Inventories, Net Inventory Disclosure [Text Block] Machinery Machinery and Equipment [Member] Subsequent Event [Table] Subsequent Event [Table] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Proceeds from debt, contingent on additional milestones Contingent Monetization Agreement, Milestone Payment Contingent Monetization Agreement, Milestone Payment Entity Tax Identification Number Entity Tax Identification Number At-the-market offering, amendment no. 1 At The Market Offering, Amendment One [Member] At The Market Offering, Amendment One Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Additional borrowing capacity Debt Instrument, Additional Borrowing Capacity Amount of debt that can be borrowed in addition to initial notes. Revenue from Contract with Customer [Abstract] Estimated annual amortization expense Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Current portion Liabilities, Sale of Future Royalties, Current Liabilities, Sale of Future Royalties, Current Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Fair value of warrants Warrants Not Settleable in Cash, Fair Value Disclosure Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Material Agreements Collaborative Arrangement Disclosure [Text Block] Customer Concentration [Abstract] Customer Concentration [Abstract] Other Other Accrued Liabilities, Current Accounting Standards Update [Domain] Accounting Standards Update [Domain] City Area Code City Area Code Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance and exercise of warrants Proceeds from Issuance and Exercise of Warrants Proceeds from Issuance and Exercise of Warrants Proceeds from common stock issued under public equity offering, net Proceeds from Issuance Initial Public Offering Vested and expected to vest as of June 30, 2022 (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, in Shares Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date in shares 2023 Long-Term Debt, Maturity, Year One Share-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Other non-current liabilities Other Liabilities, Noncurrent Loans payable, net Loans Payable, Noncurrent Capital expenditures Payments to Acquire Property, Plant, and Equipment Sale of stock, aggregate offering price Sale of Stock, Aggregate Offering Price Sale of Stock, Aggregate Offering Price Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Customer [Domain] Customer [Domain]